Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The results of subtyping the B antigen in 551 sera from patients with viral hepatitis, chronic evolutive hepatitis and cirrhosis, chronic carriers, donors and healthy subjects, were confirmed as positive HBAg by diffusion in agar, counterelectrophoresis and radioimmunology, and characterized by the d-y and w-r determinants by rheophoresis. The high incidence of the y determinant in all nine counties investigated probably reflects the prevalence of this serotype in Romania, recalling the distribution of subtypes observed in the south of Europe.
 ...
PMID:[Distribution of subtypes of viral hepatitis B antigen in areas of Rumania]. 13 42

Postmortem diagnosis of liver cirrhosis was made over a one-year period in 43 cases, 18 of which also exhibited hepatocellular carcinoma. Blood samples taken from these and 120 other patients who died from other diseases were tested for hepatitis-B antigen (HB-Ag) and its antibodies (HB-AB) by counter-electrophoresis. The types of cirrhosis found were classified on the basis of morphological characteristics and available etiological data. The greater part of controls had had cardiovascular diseases and 32 had had non-hepatic carcinoma. Age limits were similar in the cirrhotic and control groups. HB-Ag was detected in 5 of the 25 subjects with macronodular cirrhosis and in one alcoholic patient among 18 subjects with other types of cirrhosis. The possibility of a coincidental HB virus infection existed in the alcoholic case and in one case of macronodular cirrhosis. Only one patient with liver carcinoma had HB-Ag. Among the 120 controls, HB-Ag and HB-AB were found in a one case. Microscopic lesions did not seem to be related specifically to the presence of HB-Ag in the cirrhotic livers.
 ...
PMID:Hepatitis B antigen in liver cirrhosis and hepatocellular carcinoma. 17 69

Long-term treatment with prednisone and azathioprine gives satisfactory results in chronic aggressive (chronic active) hepatitis. Of 18 patients treated between 1966 and 1976 for an average of 2.9 years the disease became inactive clinically, biochemically and histologically in 13; merely two continued to have minimal activity histologically. These patients have not required any treatment for two years (on average). In one patient there are still definite signs of activity and immunosuppressive treatment is being continued. Four patients died of cirrhosis of the liver: two of them had not taken the drugs conscientiously. Death occurred on average two years after the diagnosis had been made. Of the 18 patients five were positive for hepatitis-B antigen.
 ...
PMID:[Long-term results of immunosuppressive treatment of chronic aggressive hepatitis (author's transl)]. 72 Feb 35

Oxphenisatin is known to induce liver damage and is suspected to cause or perpetuate chronic liver disease. In order to evaluate the hepatotoxic effect of long-term therapy with oxyphenisatin 26 consecutive patients with rheumatoid arthritis were investigated for the presence of liver disease. In all cases, liver biopsy, biochemical liver function tests and determination of Hepatitis-B antigen were performed. Ten patients showed no pathological changes in the liver biopsy and a further 2 had only non-specific changes. Seven patients had fatty liver, 5 passive congestion, one haemosiderosis and only one had cirrhosis of the liver. No correlation was found between the activity of rheumatoid arthritis, and duration of the disease, the drug therapy given, and the liver damage.
 ...
PMID:Morphological changes in liver biopsies from patients with rheumatoid arthritis. 93 24

The clinical, biochemical and immunological data of 24 hepatitis B antigen-positive and 24 hepatitis B antigen-negative patients have been compared. In B antigen-positive hepatitis, being mostly the disease of males, an acute onset was frequent and perceivable cirrhosis at the time of diagnosis not frequent. In B antigen-negative chronic active hepatitis, in addition to the predominance of females, a "primary chronic" process, cirrhosis, elevated ESR, immunocytopenia, elevated alkaline phosphatase and IgG levels were more frequent. As regards the positivity of humoral and cellular autoimmune reactions and the impairment of normal cellular immune activity, no essential differences were found between the two forms of the disease. It is concluded that though the two clinical conditions represent diseases different in aetiology and manifesting with certain clinical and biochemical differences the role of immunological factors may equally be important in their pathogenesis.
 ...
PMID:Clinical and immunological findings in hepatitis B antigen-positive and hepatitis B antigen-negative chronic active hepatitis. 123 58

A long-term follow-up of 45 patients with chronic hepatitis and 41 with cirrhosis is reported. Hepatitis-B antigen (HBAg) was present in 19 (42%) of the chronic hepatitis patients and in 20 (49%) of those with cirrhosis. The clinical course and biochemical and histological findings in the HBAg-positive and the HBAg-negative cases were similar, suggesting that HBAg-positive chronic liver disease is not a distinct clinical entity. The presence of antigen and autoantibodies was not found to be mutually exclusive. In HBAg-positive cases antigen tended to persist for months and years. When no irreversible lesions exist disappearance of the antigen may be a sign that the liver disease will resolve.
 ...
PMID:Chronic liver disease and hepatitis-B antigen: a prospective study. 421 93

The level of alpha-fetoprotein (AFP) was estimated by radioimmunoassay or passive hemagglutination method in a series of 159 patients with liver cirrhosis, and the incidence of serum hepatitis B antigen, histopathologic features of the liver, incidence of development of hepatocellular carcinoma (HCC) and mortality in AFP-positive cases were studied. Approximately 40 per cent of the patients had an AFP level higher than 20 ng/per ml, and all the elevations of AFP over 100 ng per ml were transient. In contrast, patients who developed HCC during the course of the disease always exhibited an increasing value of AFP. The seropositivity for AFP was significantly related to the presence of serum hepatitis B surface antigen and also to liver cell dysplasia as well as to thickening of the liver cell plates. As compared with a group of AFP-negative cases, the AFP-positive group showed a higher incidence of development of HCC and poorer prognosis over a five-year follow-up period. The data obtained suggested that increased AFP-production in patients with liver cirrhosis might reflect, largely an abnormal or altered liver cell regeneration, probably associated with hepatitis B virus, and that patients with transiently elevated AFP values might be at greater risk for the development of HCC.
 ...
PMID:Clinical implications of alpha-fetoprotein in liver cirrhosis: five-year follow-up study. 616 69

An autopsy case of pulmonary hypertension in a 29-year-old Japanese female with macronodular, posthepatic liver cirrhosis and hepatitis-B antigenemia was presented. No recognizable known cardio-pulmonary disease or portal thrombosis was obtained. Hepatitis-B antigen was demonstrated in the cirrhotic hepatocytes by a specific peroxidase antiperoxidase method. Characteristic pulmonary arterial changes including plexiform lesions with varying developmental stages were widely observed throughout the lungs. Complication of these two distinct disease processes seems to be rarely encountered in the literature. Discussion was focused on the possible interrelationship between the liver cirrhosis with hepatitis-B antigenemia and pulmonary hypertension. Proposed were presumptive underlying humoral, particularly immunological, abnormalities common to these diseases rather than mere incidental complications.
 ...
PMID:Pulmonary hypertension associated with liver cirrhosis and hepatitis-B antigenemia. 634 Feb 45